Find policies, billing codes, payers, states, and providers
Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria and limitations for cerebrospinal fluid and serum biomarker testing used to diagnose or evaluate multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and MOG-IgG–associated disease; intended for providers submitting claims to Oscar Health.
No material clinical or coverage changes in this revision.
Coverage Criteria
CSF oligoclonal band testing — Covered indications
Covered when ANY of the following are met (CSF/serum oligoclonal band analysis meets criteria):
Supports 2017 McDonald allowance for CSF OCBs substituting for dissemination in time; CSF testing should be paired with serum to demonstrate CSF-specific OCBs.
Not medically necessary / Not covered
Not covered / Do not meet criteria:
General exclusion for serum biomarkers lacking sufficient evidence.
Comparative performance favors cell-based assays/FACS over ELISA; KRONUS AQP4 ELISA should not be used alone and must be interpreted with other clinical and imaging data.
Policy recommends against general MOG-IgG testing in progressive presentations.
ELISA, Western blot, immunohistochemistry, and other non–cell‑based serum assays for detection of AQP4‑IgG or MOG‑IgG are explicitly designated as not meeting criteria. These assay types are considered insufficiently specific or sensitive for diagnosing NMOSD or MOG‑IgG–associated disease and therefore DO NOT MEET CRITERIA for coverage when used to evaluate suspected NMOSD or MOG‑EM.
All cerebrospinal fluid (CSF) biomarker tests other than CSF oligoclonal band (OCB) analysis are excluded from coverage for diagnosis of MS, NMOSD, or MOG‑EM. This includes testing for AQP4‑IgG or MOG‑IgG in CSF, which the policy states DO NOT MEET CRITERIA for these diagnoses and therefore are not covered.
The policy recommends against routine or general MOG‑IgG testing in patients with a progressive disease course because of the very low pre‑test probability in that population. Where MOG‑EM remains clinically suspected, the policy highlights best practices for MOG testing (preferred assay types and timing), but advises that general screening in progressive disease is not supported.
The KRONUS AQP4 ELISA is cited as an FDA‑cleared semi‑quantitative assay for Aquaporin‑4 autoantibodies, but the policy emphasizes that this assay "is not to be used alone". Results from the KRONUS AQP4 ELISA must be interpreted in conjunction with other clinical, laboratory, and radiological findings (for example, MRI) rather than as a standalone diagnostic determination.
Outside the specific, evidence‑based indications enumerated for CSF OCB testing and for serum AQP4‑IgG/MOG‑IgG by validated cell‑based methods (indirect fluorescence assay or FACS), the policy affirms that serum biomarker tests for multiple sclerosis and related disorders DO NOT MEET CRITERIA. Claims for such tests performed outside the defined indications may be denied or are not covered under this policy.
Coding and Procedure Codes
| No codes listed |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified. |
| 83884 | Neurofilament light chain (NfL). |
| 83916 | Oligoclonal immune (oligoclonal bands). |
| 86052 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; cell-based immunofluorescence assay (CBA), each. |
| 86362 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each. |
| 88341 | Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure). |
| 88342 | Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure. |
| Proprietary | Neurofilament Light Chain (NfL) ultra-sensitive immunoassay, serum or cerebrospinal fluid — Proprietary test; Lab/Manufacturer: Neuromuscular Clinical Laboratory at Washington University in St. Louis School of |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified. |
| 83884 | Neurofilament light chain (NfL). |
| 83916 | Oligoclonal immune (oligoclonal bands). |
| 86052 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; cell-based immunofluorescence assay (CBA), each. |
| 86362 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each. |
| 88341 | Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure). |
| 88342 | Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure. |
Provider Actions and Billing Guidance
Verify benefits and obtain prior authorization when required
Coverage and application of the policy criteria depend on the member's benefit coverage at the time of the request; specified biomarker tests meet criteria only in defined clinical situations and may require prior authorization per member benefits. Verify benefits and obtain authorization as needed before ordering/testing to confirm coverage.
Include listed CPT/HCPCS procedure codes in authorization requests
When requesting prior authorization or verifying coverage, reference the policy's listed procedure codes for the specific assays (e.g., 83520, 83884, 83916, 86052, 86362, 88341, 88342) so the payer can identify the test(s) under review.
Prior authorization may be required for listed procedure codes
Certain biomarker assays enumerated in the policy are associated with CPT/HCPCS codes and may require prior authorization per the member's benefit plan; follow the payer's PA process for these codes prior to testing.
- Follow payer prior authorization process for listed procedure codes when required.
Account for therapy class when ordering/interpreting sNfL
sNfL (serum neurofilament light chain) Z-scores decline to control-group levels with high-efficacy monoclonal antibody therapies, decline less with oral therapies, and do not decrease with platform compounds (e.g., interferons, glatiramer acetate); interpret sNfL results in the context of therapy class when using sNfL for monitoring.
- Decreased sNfL Z-scores with monoclonal antibodies suggest treatment response.
- Smaller decreases with oral therapies; no decrease with platform compounds—consider therapy class when ordering/interpreting sNfL.
No step therapy requirements specified in this policy
No step therapy requirements are specified in this policy; there are no policy-imposed sequencing or step edits for the biomarker tests described.
Provide accurate documentation to support medical necessity and authorization
Submit accurate clinical documentation that demonstrates medical necessity and meets authorization criteria for the ordered biomarker test(s); providers are responsible for documentation and claims may be denied or recouped if documentation or coding is inadequate.
- Provide clinical rationale and supporting records when requesting authorization or submitting claims.
- Ensure coding follows industry standard guidelines to avoid denials or recoupment.
Always submit paired serum with CSF OCB testing
When performing CSF oligoclonal band testing for MS diagnosis, submit paired serum with the CSF sample so OCBs unique to CSF can be demonstrated; the International Panel and policy require CSF be paired with serum.
- Include a contemporaneous serum specimen with CSF OCB testing to show CSF-specific OCBs.
Document validated test method and clinical correlation (MRI/clinical findings)
Document use of validated laboratory methods and provide clinical correlation (e.g., MRI findings, clinical presentation) when ordering LDTs or FDA-cleared assays; support test selection and interpretation with imaging and clinical data per the policy.
- Indicate the assay type (e.g., cell-based assay/FACS) and laboratory validation status when available.
- Attach relevant MRI or clinical findings to support the test's diagnostic use.
Tests that do not meet criteria or lack documentation risk denial/recoupment
Claims for tests marked 'DO NOT MEET CRITERIA' (e.g., most serum biomarker assays outside specified indications, ELISA/Western blot/IHC for NMOSD/MOG-EM) or claims with inadequate supporting documentation may be denied or recouped; ensure tests ordered meet the policy's coverage criteria and are coded appropriately.
- Do not bill for serum assays or CSF biomarkers excluded by policy unless clinical criteria are met and documented.
- Provide complete supporting documentation with claims to avoid denials/recoupment.
Follow applicable government (Medicare/Medicaid) policies when conflicts exist
If there is a conflict between this policy and an applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid coverage), the government policy controls; follow applicable Medicare/Medicaid rules for coverage determinations.
Billing with listed procedure codes may be denied if policy criteria or documentation are not met
Claims billed with the CPT/HCPCS procedure codes listed in the policy (e.g., 83520, 83884, 83916, 86052, 86362, 88341, 88342) may be denied if the test does not meet the policy's coverage criteria or if coding/documentation is inappropriate; verify medical necessity and proper coding prior to billing.
- Confirm the test meets policy criteria before submitting claims with the listed CPT/HCPCS codes.
- Ensure code selection aligns with the assay method (e.g., CBA/FACS vs ELISA) as described in the policy.
Background
Multiple sclerosis (MS) is an immune‑mediated demyelinating disease of the central nervous system with variable clinical courses, including relapsing‑remitting, secondary progressive, and primary progressive forms. Diagnosis depends on demonstration of dissemination in time and space using clinical evaluation and MRI; cerebrospinal fluid oligoclonal IgG bands (OCBs) represent intrathecal IgG synthesis and can be an important adjunctive test. In appropriate clinical contexts, CSF‑specific OCBs may substitute for dissemination in time under established diagnostic criteria, and the policy therefore defines specific situations in which CSF OCB testing meets criteria as a diagnostic aid.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.